Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 18;14:5781. doi: 10.1038/s41467-023-41529-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Lung images of mice observed using micro-CT scans after treatments on Day 28 post initial administration of BLM. The yellow arrows indicate the fibrotic features. b Representative lung images of H&E staining and Masson’s trichrome staining of mice with different treatments on Day 28, NT indicates the no treatment groups. Scale bar, 500 μm. The fibrotic ratio was calculated by measuring the percentage of blue area within the pulmonary sections (n = 18, six fields of view from three independent lung sections). c Relative collagen expression in the lung of mice after the indicated treatments (n = 3 biologically independent samples). Expression of d MMP9 and e TGF-β in the bronchoalveolar fluids after the indicated treatments (n = 10 biologically independent samples for each). f Hydroxyproline content in lung homogenates after the indicated treatments (n = 8 biologically independent samples). g Observations of mitochondrial morphology using TEM. Scale bars, 2 μm. Green indicates healthy mitochondria and brown indicates impaired mitochondria. h Area of mitochondria (n = 97 in the healthy group, n = 93 in the NT group, n = 66 in the hMSC group, n = 79 in the Pg-hMSC group, n = 59 in the Fe-hMSC group, n = 74 in the Pg-Fe-hMSC group, mitochondria counted from six independent lung sections for each group) measured according to TEM observations. i Perimeter of mitochondria calculated according to TEM observations (same replicates as h). j Ratios of healthy mitochondria according to morphological observations (n = 6 biologically independent samples). k Representative lung images following H&E staining and Masson’s trichrome staining after the indicated treatments. Scale bar, 500 μm. l Fibrotic ratio of mice’s lungs after the indicated treatments. The ratio was calculated by measuring the percentage of blue area within the pulmonary sections (n = 18, six fields of view from three independent lung sections). Expression of m MMP9, n TGF-β, and o Hydroxyproline in the bronchoalveolar fluid after the indicated treatments (n = six biologically independent samples for each). Data are presented as means ± SD. Statistical significance was analyzed using ordinary one-way ANOVA.